Literature DB >> 11213476

Thioredoxin blood level increases after severe burn injury.

A Abdiu1, H Nakamura, B Sahaf, J Yodoi, A Holmgren, A Rosén.   

Abstract

We have investigated the thioredoxin (TRX) levels in severely burned patients and the possible origin of TRX, based on the recent understanding that TRX is a potent antioxidant with cytoprotective functions. Serum and plasma samples from burns patients and healthy blood donors were collected during the first 10 post-burn days and analyzed in a sandwich TRX enzyme-linked immunosorbent assay (ELISA). The TRX levels found were correlated to a panel of blood tests. The presence of TRX in platelets was investigated by immunoelectron microscopy and Western blotting. TRX serum levels of the severely burned patients showed a significant increase, with a mean serum TRX concentration on the day of injury of 76.5 +/- 19.5 ng/ml (mean +/- SD) and on post-burn day one 122.6 +/- 66.9 ng/ml, compared to control blood donor levels of 22.7 +/- 12.2 ng/ml (p = 0.0041 and 0.0117, respectively). A second peak of increase was found on post-burn days 7 to 9 with a four- to five-fold rise in concentration compared to controls. TRX elevation correlated well with increased platelet (p = 0.007) and leukocyte counts (p = 0.002). We also demonstrated by immunoelectron microscopy and Western blotting the presence of TRX in platelets. In conclusion, our demonstration of TRX release in burn injuries indicates that the TRX system is involved in a rapid antioxidant defense, coagulation processes, cell growth, and control of the extracellular peroxide tone intimately linked to cytoprotection and wound healing in burns. One of the cell types that delivers TRX promptly and efficiently into the blood may be the platelet.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11213476     DOI: 10.1089/ars.2000.2.4-707

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  14 in total

1.  A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.

Authors:  Ramesh K Ramanathan; Joe J Stephenson; Glen J Weiss; Linda A Pestano; Ann Lowe; Alton Hiscox; Rafael A Leos; Julie C Martin; Lynn Kirkpatrick; Donald A Richards
Journal:  Invest New Drugs       Date:  2011-08-24       Impact factor: 3.850

2.  Changes in thioredoxin concentrations: an observation in an ultra-marathon race.

Authors:  Mitsuhiro Marumoto; Sadao Suzuki; Akihiro Hosono; Kazuyuki Arakawa; Kiyoshi Shibata; Mizuho Fuku; Chiho Goto; Yuko Tokudome; Hideki Hoshino; Nahomi Imaeda; Masaaki Kobayashi; Junji Yodoi; Shinkan Tokudome
Journal:  Environ Health Prev Med       Date:  2009-12-04       Impact factor: 3.674

3.  Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate.

Authors:  Shoko Tsuchikura; Tetsuo Shoji; Naoko Shimomura; Ryusuke Kakiya; Masanori Emoto; Hidenori Koyama; Eiji Ishimura; Masaaki Inaba; Yoshiki Nishizawa
Journal:  BMC Nephrol       Date:  2010-04-27       Impact factor: 2.388

4.  Redox responses in patients with sepsis: high correlation of thioredoxin-1 and macrophage migration inhibitory factor plasma levels.

Authors:  Thorsten Brenner; Claudia Rosenhagen; Jochen Steppan; Christoph Lichtenstern; Jürgen Weitz; Thomas Bruckner; Eike O Martin; Ursula Hoffmann; Markus A Weigand; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

5.  Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.

Authors:  Jinping Fan; Haiying Yu; Ying Lv; Liguo Yin
Journal:  Tumour Biol       Date:  2015-09-03

Review 6.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

7.  Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1.

Authors:  F H Passam; S Rahgozar; M Qi; M J Raftery; J W H Wong; K Tanaka; Y Ioannou; J Y Zhang; R Gemmell; J C Qi; B Giannakopoulos; W E Hughes; P J Hogg; S A Krilis
Journal:  J Thromb Haemost       Date:  2010-08       Impact factor: 5.824

8.  Bioinformatics analysis of the early inflammatory response in a rat thermal injury model.

Authors:  Eric Yang; Timothy Maguire; Martin L Yarmush; Francois Berthiaume; Ioannis P Androulakis
Journal:  BMC Bioinformatics       Date:  2007-01-10       Impact factor: 3.169

9.  Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.

Authors:  Jun Li; Zhang-Jun Cheng; Yang Liu; Zhen-Lin Yan; Kui Wang; Dong Wu; Xu-Ying Wan; Yong Xia; Wan Yee Lau; Meng-Chao Wu; Feng Shen
Journal:  Oncotarget       Date:  2015-04-20

10.  Plasma thioredoxin levels during post-cardiac arrest syndrome: relationship with severity and outcome.

Authors:  Nicolas Mongardon; Virginie Lemiale; Didier Borderie; Anne Burke-Gaffney; Sébastien Perbet; Nathalie Marin; Julien Charpentier; Frédéric Pène; Jean-Daniel Chiche; Jean-Paul Mira; Alain Cariou
Journal:  Crit Care       Date:  2013-01-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.